MSD in Australia has announced
that the new Nasonex Allergy
Nasal Spray (mometasone furoate)
for limited Allergic Rhinitis (AR),
is available over the counter as
a Schedule 2 (S2) medicine from
mid-July.
The product has an identical
formulation to the prescription
Nasonex, with 50 μgm per actuation.
Dosage instructions are also
identical for the same AR patients
for whom they are indicated.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.